MedTrace Logo

Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL

NCT07677878 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-07-01

No results posted yet for this study

Summary

This prospective study will be conducted in high-risk B-ALL patients post-allo-HSCT. We propose to investigate the safety and therapeutic efficacy of blinatumomab plus low-dose DLI maintenance therapy, with the ultimate goal of enhancing long-term survival outcomes.

Conditions

  • ALL (Acute B-Lymphoblastic Leukemia)

Interventions

DRUG

Blinatumomab Injection

blinatumomab 9ug d1-7, 28ug d8-14

OTHER

Donor Lymphocyte Infusion (DLI)

CD3+cell 1×10\^5/kg

Sponsors & Collaborators

  • Liping Dou

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-01
Primary Completion
2028-11-30
Completion
2028-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07677878 on ClinicalTrials.gov